Prescient Acquires Dolon to Expand Drug Pricing Capabilities

Prescient Healthcare Group has acquired Dolon, a market access and pricing consultancy, in a move that signals growing demand for specialized expertise in one of the pharmaceutical industry's most scrutinized—and lucrative—disciplines. The deal, announced March 30, brings together two firms that have spent years helping drugmakers navigate the increasingly complex terrain between clinical development and commercial launch.

Financial terms weren't disclosed, which is typical for mid-market professional services deals. But the acquisition's timing reveals something about where the life sciences consulting market is headed: toward integrated advisory that can guide a molecule from Phase II trials through patent expiration, with pricing strategy woven throughout.

Dolon brings roughly two dozen consultants to Prescient, along with a client roster that spans biotech startups and established pharmaceutical companies. More importantly, it brings a track record in health economics and outcomes research (HEOR), payer engagement strategy, and the kind of pricing architecture work that now starts years before a drug hits the market.

For Prescient, which already operates across clinical development, regulatory strategy, and commercialization, the acquisition fills what CEO Matt Grasinger describes as a critical capability gap. "Our clients were asking us to stay engaged through market access and pricing strategy," he said in the announcement. "This wasn't about adding a service line—it was about not handing off the relationship at the moment when value demonstration becomes everything."

The appetite for pricing and market access consulting has intensified as pharmaceutical companies face simultaneous pressure from multiple directions. Payers are demanding more sophisticated evidence of clinical and economic value. Regulators in the U.S. and Europe are tightening scrutiny on launch pricing and post-approval price increases. And patients are increasingly vocal about affordability, turning what was once a backroom negotiation into a public relations battlefield.

Meanwhile, the stakes keep climbing. A single pricing misstep—launching too high and triggering backlash, or too low and leaving billions on the table—can define a product's trajectory for years. That's created a market for consultants who can model payer responses, stress-test value propositions, and advise on pricing architecture across different geographies and reimbursement systems.

Dolon has built its reputation in this space by working at the intersection of clinical evidence and commercial strategy. The firm helps clients design outcomes studies that will resonate with payers, develop value dossiers that support pricing decisions, and engage with health technology assessment bodies in markets like the U.K., Germany, and Canada where those agencies wield significant influence over market access.

What Prescient gets with the acquisition isn't just more consultants—it's access to methodologies and relationships that typically take years to build. Dolon's team includes health economists, former payer medical directors, and pricing strategists who've worked inside pharmaceutical companies. That blend of perspectives is hard to replicate through organic growth alone.

The most immediate value of the deal lies in integration—being able to advise a client from late-stage clinical development through launch and lifecycle management without switching firms. That continuity matters because pricing strategy now starts much earlier in development than it used to.

Ten years ago, pricing conversations typically began 18-24 months before launch. Now, companies are thinking about pricing architecture during Phase II, when trial design decisions can still be influenced by what payers will want to see. Endpoint selection, comparator choice, and patient population definition all have downstream pricing implications.

Prescient and Dolon both already worked with clients across this continuum, but often in parallel rather than in partnership. The acquisition eliminates that handoff. A biotech client working with Prescient on clinical strategy can now transition seamlessly to pricing and market access planning with the same advisory team, which in theory means fewer gaps, less redundant work, and a more coherent go-to-market strategy.

The table above shows how pricing strategy timelines have shifted earlier into the development process, creating demand for advisory firms that can operate across multiple phases without losing continuity.

Another dimension of the deal: Dolon brings deeper expertise in European health technology assessment (HTA) processes, which have become more important as drug pricing negotiations in markets like Germany, France, and the U.K. increasingly hinge on formal value assessments. Prescient has worked with European clients, but hasn't had the same depth of HTA expertise in-house. That gap matters as biopharma companies face diverging pricing and reimbursement landscapes across geographies.

Prescient's move fits into a wider pattern of consolidation among life sciences consultancies. Over the past three years, firms specializing in niche areas—regulatory affairs, pharmacovigilance, real-world evidence, market access—have increasingly been acquired by larger platforms looking to offer end-to-end services.

The logic is straightforward: pharmaceutical and biotech companies prefer fewer vendor relationships, especially when those vendors need to coordinate across functions. A consultant advising on clinical trial design needs to understand the regulatory pathway. A regulatory strategist needs to anticipate payer evidence requirements. A pricing consultant needs to know what the clinical data can and can't support.

Private equity firms have noticed. Several PE-backed life sciences consultancies have gone on acquisition sprees, building multi-service platforms that can compete for larger, longer-term contracts. Prescient itself is backed by private equity sponsor Sverica Capital Management, which took a stake in the firm in 2023.

Dolon had remained independent until now, which made it an attractive target. Independent boutique consultancies often have strong client relationships and deep expertise, but lack the capital and infrastructure to scale rapidly. For firms like Prescient, acquiring these boutiques is faster and less risky than trying to build those capabilities organically.

The question is whether integration actually delivers on the promise. Merging consulting firms is notoriously difficult—cultures clash, key employees leave, clients get nervous about changes to their advisory teams. Prescient's bet is that it can retain Dolon's team and expertise while plugging them into a larger platform with more resources.

In professional services M&A, the assets walk out the door every night. If Dolon's senior consultants decide they don't like the new setup and leave, Prescient will have overpaid for a client list and a brand name. Retention packages and earnouts are standard tools to mitigate this risk, but they don't guarantee culture fit.

Prescient's announcement emphasized that Dolon's leadership team will remain in place and that the firm will operate as a distinct practice area within Prescient, at least initially. That's a common playbook—maintain some autonomy in the early stages, then integrate more deeply over time as trust builds.

For the biotech and pharmaceutical companies that hire firms like Prescient and Dolon, the acquisition creates both opportunity and uncertainty. On the positive side, integrated advisory could mean fewer handoffs, better continuity, and consultants who understand both the clinical and commercial sides of a program.

On the other hand, consolidation reduces options. If Prescient-Dolon becomes a dominant player in the pricing and market access space, clients may find they have fewer credible alternatives when negotiating scope and fees. That's not an immediate concern—there are still dozens of independent market access consultancies—but the trend is worth watching.

There's also a question about objectivity. When the same firm is advising on clinical strategy, regulatory positioning, and pricing, there's a risk that recommendations become shaped by internal cross-selling incentives rather than purely by what's best for the client. Prescient will need to demonstrate that its integrated model doesn't compromise the independence of its advice.

Still, for companies launching complex therapies—particularly in areas like gene therapy, cell therapy, or rare diseases where pricing is contentious and payer negotiation is intensive—the appeal of a single advisory partner that can guide the entire journey is real. These aren't products where you can copy the playbook from a prior launch. Every program needs bespoke strategy, and having that strategy developed by a team that's been involved from Phase II onward could reduce the risk of late-stage surprises.

The backdrop to all of this is a policy environment where drug pricing remains a political flashpoint. In the U.S., the Inflation Reduction Act's Medicare negotiation provisions have changed the calculus for how companies think about pricing over a product's lifecycle. In Europe, governments are pushing for greater transparency in pricing decisions and more aggressive use of cost-effectiveness thresholds.

That environment creates demand for sophisticated modeling and scenario planning—exactly the kind of work that firms like Dolon specialize in. Companies need to understand how different pricing strategies will play out not just at launch, but five and ten years down the line as patents expire, biosimilars enter, and payer leverage increases.

The regional complexity of drug pricing creates opportunities for consultancies that can navigate multiple reimbursement systems simultaneously, which is part of what makes Dolon's geographic reach valuable to Prescient.

What's less clear is whether the consulting industry's consolidation will itself attract regulatory scrutiny. If a handful of firms end up advising most pharmaceutical companies on pricing strategy, that could raise questions about whether those firms are contributing to industry-wide pricing patterns that policymakers view as problematic.

Prescient hasn't disclosed a formal integration timeline, but these deals typically unfold over 12-24 months. The early phase focuses on retention—making sure Dolon's team stays put and clients don't bolt. The middle phase involves operational integration—combining back-office functions, aligning methodologies, cross-training teams. The final phase is about leveraging the combined platform to win larger contracts that neither firm could have pursued independently.

If the integration goes well, Prescient will likely use this acquisition as a template for further deals. There are still plenty of independent consultancies in adjacent areas—real-world evidence, patient access programs, value-based contracting—that could be folded into a larger platform. Sverica Capital Management's typical playbook involves multiple acquisitions over a 5-7 year hold period, so this probably isn't Prescient's last deal.

If the integration stumbles—if key employees leave, if clients push back on the new structure, if the cultures don't mesh—then Prescient will have a more expensive problem to solve. But the fact that the firm felt confident enough to announce the deal publicly, without waiting for integration milestones, suggests they believe the risk is manageable.

For now, the deal represents a bet that the future of life sciences consulting is integrated, not specialized. That's a thesis worth watching, because if Prescient is right, expect more acquisitions like this one. And if they're wrong, expect the independent boutiques to have a resurgence.